Truvestments Capital’s Akebia Therapeutics AKBA Stock Holding History

Truvestments Capital’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.05K	Hold	756	–	–	﹤0.01%	1050
2025 Q4	$1.22K	Hold	756	–	–	﹤0.01%	911
2025 Q3	$2.06K	Hold	756	–	–	﹤0.01%	918
2025 Q2	$2.75K	Hold	756	–	–	﹤0.01%	802
2025 Q1	$1.45K	Hold	756	–	–	﹤0.01%	903
2024 Q4	$1.44K	Hold	756	–	–	﹤0.01%	886
2024 Q3	$998	Buy	+756	New	+$1.01K	﹤0.01%	853
2024 Q2	–	Sell	-756	Closed	-$1.38K	–	236
2024 Q1	$1.38K	Hold	756	–	–	﹤0.01%	634
2023 Q4	$937	Hold	756	–	–	﹤0.01%	713
2023 Q3	$862	Hold	756	–	–	﹤0.01%	628
2023 Q2	$692	Hold	756	–	–	﹤0.01%	648
2023 Q1	$424	Hold	756	–	–	﹤0.01%	637
2022 Q4	$436	Hold	756	–	–	﹤0.01%	874
2022 Q3	$0	Sell	756 -144	-16%	-$57	﹤0.01%	619
2022 Q2	$0	Buy	+900	New	+$378	﹤0.01%	641
2022 Q1	–	Sell	-900	Closed	-$2K	–	192
2021 Q4	$2K	Hold	900	–	–	﹤0.01%	542
2021 Q3	$3K	Hold	900	–	–	﹤0.01%	496
2021 Q2	$3K	Hold	900	–	–	﹤0.01%	502
2021 Q1	$3K	Buy	900 +405	+82%	+$1.46K	﹤0.01%	561
2020 Q4	$1K	Buy	+495	New	+$1.45K	﹤0.01%	578
2020 Q3	–	Sell	-495	Closed	-$6K	–	319
2020 Q2	$6K	Buy	+495	New	+$5.12K	0.01%	442
2019 Q4	–	Sell	-861	Closed	-$3K	–	152
2019 Q3	$3K	Sell	861 -74	-8%	-$317	﹤0.01%	619
2019 Q2	$5K	Hold	935	–	–	﹤0.01%	608
2019 Q1	$8K	Buy	+935	New	+$6.42K	0.01%	533
2018 Q3	$8K	Buy	+960	New	+$8.59K	﹤0.01%	672

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Truvestments Capital's AKBA Position: Q1 2026 in Review

Truvestments Capital held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 756 shares worth $1.05K. The position accounts for ﹤0.01% of the portfolio, ranked #1050.

Truvestments Capital first reported a position in AKBA in Q3 2018 and has held it in 25 quarters since. The position peaked at $8K in Q1 2019. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Truvestments Capital held 756 shares of Akebia Therapeutics worth $1.05K as of Q1 2026.
Truvestments Capital left its Akebia Therapeutics share count unchanged in Q1 2026.
Akebia Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #1050 holding.
Truvestments Capital first reported a position in Akebia Therapeutics in Q3 2018 and has held it in 25 quarters since.
Truvestments Capital's Akebia Therapeutics position peaked at $8K in Q1 2019.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.